Tagged: life-sciences
30 results
Embleema
Embleema is a New York- and France-based healthcare technology company that builds a unified real-world data and evidence platform for clinical research. It aggregates clinical, genomic, and patient-reported data from electronic medical records, wearables, biospecimens, and patient apps into regulatory-grade datasets, and uses no-code protocol tools plus dynamic consent to help pharmaceutical sponsors, research sites, and patient groups run non-interventional and Phase IV studies faster and at lower cost. Founded in 2017 by Robert Chu, the company started with a patient-driven health blockchain and its analytics stack has been used by the FDA for genomic regulatory review.
Fount Bio, Inc.
Fount Bio is a Somerville, Massachusetts life-science company that builds long-lasting hyaluronic acid (HA) matrices directly inside living tissue. Its proprietary Flī-HA platform uses Nobel-Prize-winning bioorthogonal (click) chemistry to deliver HA building blocks that self-assemble in situ into a biostable, high-molecular-weight matrix - overcoming the delivery and degradation barriers that have long forced HA to be injected as pre-formed filler. The lead product, Flī-Derm, is a needle-free liquid for aesthetic dermatology that reduced fine lines and wrinkles in a blinded clinical study and won IMCAS 2024's Innovation of the Year. The tunable platform extends toward ophthalmology, joints, mucosal tissue and women's health.
IgniteData
IgniteData is a healthtech company automating the transfer of clinical trial data between hospital electronic health records (EHRs) and sponsors' electronic data capture (EDC) systems. Its flagship platform, Archer, is a cloud-based, system-agnostic 'Virtual Research Assistant' that uses HL7 FHIR and SMART on FHIR APIs to move clinically validated data securely and automatically, cutting manual transcription, reducing source data verification, and helping treatments reach patients faster. Founded in the UK and now operating on both sides of the Atlantic, IgniteData works with pharmaceutical sponsors like AstraZeneca and research hospitals including UCLH, Cambridge University Hospitals, and Memorial Sloan Kettering Cancer Center.
MDClone
MDClone is a healthcare data company that lets clinicians, researchers, and analysts explore patient data without touching real patient records. Its ADAMS platform ingests structured and unstructured health-system data into a longitudinal database, then generates statistically faithful synthetic data that carries no risk to patient privacy. That combination turns months-long, IRB-heavy data requests into self-service exploration, letting front-line staff ask their own questions, run analyses, and share results across organizations. Founded in Israel in 2016 and used across the U.S., Canada, and 100% of the Israeli healthcare market, MDClone has raised roughly $112M to expand data-driven discovery in health systems, government, payers, and life sciences.
Neion Bio
Neion Bio is a New York biotech company that genetically engineers chicken eggs into factories for complex biologic drugs. Its Raptor platform aims to make monoclonal antibodies and other glycosylated proteins at a fraction of the capital cost and carbon footprint of conventional cell-culture bioreactors. Founded in 2024 and emerged from stealth in March 2026, the company raised an oversubscribed $23 million Series A in June 2026 and signed an early multi-product biosimilar deal with a major global pharmaceutical company.
PIC Therapeutics
PIC Therapeutics is a Natick, Massachusetts biotechnology company developing small-molecule precision medicines that target cancer at the level of protein translation. Rather than chasing individual oncogenes one at a time, PIC modulates the Pre-Initiation Complex (PIC) and the translation factor eIF4E - a convergence point for many oncogenic signaling pathways - to selectively shut down the production of cancer-driving proteins while sparing healthy cells. Founded on the research of Harvard structural biologist Gerhard Wagner and led by CEO Katherine Bowdish, the company is advancing an allosteric eIF4E modulator toward first-in-human studies in drug-resistant metastatic breast cancer, backed by a $35M Series A led by OrbiMed.
Complete Genomics
Complete Genomics is a San Jose-based life-science technology company and the Americas arm of MGI. Founded in 2005 as a pioneer of affordable whole-human-genome sequencing, it develops and sells next-generation sequencing instruments, reagents, and analysis software built on its proprietary PCR-free DNBSEQ (DNA nanoball) technology. The company aims to drive down the cost of sequencing - from the landmark $5,000 genome to sub-$100 - and supplies researchers, clinical labs, and biotech companies with a full workflow spanning sample prep, library construction, sequencing, and data analysis.
Dynavax Technologies
Dynavax Technologies is an Emeryville, California biopharmaceutical company built around CpG 1018, a proprietary vaccine adjuvant that sharpens the immune system's response. Its flagship product, HEPLISAV-B, is the first and only two-dose adult hepatitis B vaccine approved in the U.S. and Europe, and had grown to roughly 44% U.S. market share by the end of 2024. Beyond hepatitis B, Dynavax licenses CpG 1018 to other vaccine developers - most visibly as an ingredient in several COVID-19 vaccines - and has advanced its own pipeline in shingles, plague, pandemic influenza, and Lyme disease. In December 2025 Sanofi agreed to acquire Dynavax for about $2.2 billion; the deal closed in February 2026.
FibroGen, Inc.
FibroGen, Inc. is a San Francisco biopharmaceutical company that spent three decades building first-in-class medicines around hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology. Its best-known drug, roxadustat, is an oral treatment for anemia approved in China, Japan and Europe. After selling its China business to AstraZeneca in 2025 and paying down debt, the company rebranded as Kyntra Bio (Nasdaq: KYNB) in January 2026 to concentrate on oncology and rare disease, led by FG-3246, a first-in-class CD46-targeting antibody-drug conjugate for metastatic prostate cancer.
Flagship Pioneering
Flagship Pioneering is a Cambridge, Massachusetts life-sciences enterprise that invents, builds, and funds companies rather than merely investing in them. Founded in 1999 by Noubar Afeyan, the firm runs a systematic 'venture creation' engine - generating scientific hypotheses in-house, prototyping them in its own labs, and spinning validated concepts into independent operating companies in human health and sustainability. Its portfolio has produced more than 100 ventures, including Moderna, and it directs roughly $14 billion in capital.
Karius
Karius is a Redwood City, California life-sciences company that turns a single blood draw into a broad infectious-disease diagnosis. Its flagship Karius Test uses microbial cell-free DNA (mcfDNA) sequencing, metagenomics and AI to detect more than 1,000 pathogens - bacteria, DNA viruses, fungi and parasites - often within a day of receiving a sample. Founded in 2014 out of Stephen Quake's lab at Stanford, the company aims to give clinicians a fast, non-invasive alternative to invasive biopsies and slow cultures, with a focus on the immunocompromised patients who need answers most urgently.
Apostle Inc
Apostle Inc is a Pleasanton, California biotechnology company that develops nucleic acid isolation and preservation technologies for liquid biopsy. Its flagship magnetic-nanoparticle kit, Apostle MiniMax, extracts circulating cell-free DNA and RNA from blood for applications in early cancer detection, non-invasive prenatal testing, infectious disease research, and even astronaut biospecimen collection in commercial spaceflight. Founded in 2018 out of the Stanford StartX accelerator, the company sells reagents, automation instruments, and CLIA/CAP lab services to researchers and diagnostics developers worldwide.
Nuvig Therapeutics
Nuvig Therapeutics is a clinical-stage biotech in the San Francisco Bay Area developing next-generation immune modulators for chronic autoimmune and inflammatory diseases. Founded in 2022 on research from The Rockefeller University, its lead candidate NVG-2089 is a first-in-class recombinant Fc fragment that engages type II Fc receptors to recapitulate the anti-inflammatory benefits of IVIg without immunosuppression or the supply constraints of plasma-derived products. The company raised a $161M Series B in December 2024 to push NVG-2089 into Phase 2 for CIDP and other indications.
Sean X. Hu
Sean X. Hu is the President and CEO of Rapafusyn Pharmaceuticals, a Baltimore-based biotech spun out of Johns Hopkins that is building a library of natural-product-like macrocycles it calls RapaGlues. He is a genomics PhD turned Wharton MBA turned management consultant turned operator, with prior stops at Bristol Myers Squibb, CuraGen, Illumina, AT Kearney, IMS, Bionest, BioStrat, GlobalData, and Avotres. In September 2025 he closed an oversubscribed $44M Series A led by BioTrack Capital and Yonjin Capital to push RapaGlues into difficult-to-drug targets.
Stan Abel
Stan Abel is President and CEO of ProJenX, a clinical-stage biotech spun out of Columbia University research and Project ALS, racing to get its lead drug prosetin - an oral MAP4K inhibitor - into ALS patients after two decades of laboratory work and a $15 million Series A.
John Crowley
John Francis Crowley is the President & CEO of the Biotechnology Innovation Organization (BIO), the world's largest biotech trade association with 1,100+ member companies in 30+ countries. A Georgetown and Harvard Business School alumnus, Navy Reserve veteran who served in Afghanistan, and author of 'Chasing Miracles,' Crowley co-founded Novazyme Pharmaceuticals - which sold to Genzyme for ~$175-200 million - and later built Amicus Therapeutics from a 5-person startup into a global biopharmaceutical company. His life story inspired the 2010 CBS Films feature 'Extraordinary Measures,' in which Brendan Fraser portrayed him alongside Harrison Ford. Since taking the helm at BIO in March 2024, he has repositioned the organization around U.S. biotech competitiveness, FDA modernization, and patient advocacy.
Laura E. Benjamin
Laura E. Benjamin is the CEO and President of Myris Therapeutics, a Pittsburgh-based biotech building ultra-high DAR antibody-drug conjugates that fuse polymer chemistry with cancer biologics. A molecular biologist by training, she has moved from Harvard pathology labs to Eli Lilly oncology leadership to two CEO chairs - most recently steering OncXerna through more than $100 million in clinical-stage financing before taking the helm at Myris in 2024.
Avenue Biosciences
Avenue Biosciences is a transatlantic biotech building the first platform to measure and modulate the cellular secretory pathway at scale. Spun out of the University of Helsinki and headquartered between Helsinki and Palo Alto, the company pairs high-throughput chemistry with machine learning to design signal peptides and boost yields of therapeutic proteins - biologics, biosimilars, and mRNA-encoded medicines - so that production bottlenecks stop limiting which therapies reach patients.
Nextnet
Nextnet is a San Francisco-based life sciences AI platform that unifies the world's biomedical data into a semantic web, helping researchers find evidence-backed answers and connections across literature, genes, drugs, targets, and diseases. Its products - Nextnet Copilot and Nextnet Explorer - serve researchers at institutions including Harvard, MIT, UCSF, MD Anderson, and Columbia.
Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company based in San Francisco that develops targeted small-molecule therapies for ER+/HER2- metastatic breast cancer and other women's cancers. Its lead candidate, palazestrant (OP-1250), is an oral complete estrogen receptor antagonist and selective ER degrader now in two Phase 3 trials, while a second program, OP-3136, is a KAT6 inhibitor in Phase 1. Olema's bet is that better-designed oral endocrine therapy can overcome the resistance that limits today's standard of care.
Biorce
Biorce is a Barcelona-based healthtech company building AI-native infrastructure for clinical trials. Its core product, Aika, helps pharmaceutical companies, biotechs and CROs design regulator-ready trial protocols in roughly 90 seconds, drawing on a corpus of more than one million clinical studies and 260,000+ protocols. By cutting protocol design time by at least 50% and flagging regulatory and feasibility risks early, Biorce aims to compress the years and billions of dollars it takes to bring a drug to market - so treatments reach patients sooner. In February 2026 it closed a USD $52.5M Series A led by DST Global, the largest Series A to date in the Iberian healthtech and AI ecosystem.
ClinChoice
ClinChoice is a mid-size, global, full-service contract research organization (CRO) that helps pharmaceutical, biotech, medical device, and consumer health companies run clinical trials and bring drugs and devices to market. Founded in 1995 and headquartered in Horsham, Pennsylvania, the firm employs roughly 4,000 people across the Americas, Europe, and Asia-Pacific, offering clinical development, biometrics, safety/pharmacovigilance, regulatory affairs, post-marketing real-world evidence, and technology services. After rebranding from Fountain Medical Development (FMD K&L) in 2020 and raising a $150M Series E in 2022, ClinChoice has grown through acquisitions to serve six of the top ten pharma companies while focusing on emerging and mid-size biotech innovators.
Elysium Health
Elysium Health is a New York-based cellular health company that turns peer-reviewed aging research into consumer products. Founded in 2014 by entrepreneur Eric Marcotulli, operator Dan Alminana, and MIT aging biologist Leonard Guarente, it pairs a scientific advisory board stacked with Nobel laureates with a direct-to-consumer model. Its flagship supplement Basis raises NAD+ levels tied to cellular energy, and its Index test estimates biological age from a saliva sample using epigenetic methylation analysis.
Nilo Therapeutics
Nilo Therapeutics is a New York-based biotechnology company developing a new class of medicines that target the brain-body neural circuits regulating the immune system. Building on discoveries that identified specific vagal neurons controlling systemic inflammation, Nilo aims to restore immune homeostasis centrally rather than broadly suppress the immune system, offering a differentiated approach to treating autoimmune and inflammatory disease. The company launched out of stealth in October 2025 with a $101 million Series A.
Noveome Biotherapeutics, Inc.
Noveome Biotherapeutics is a Pittsburgh clinical-stage biopharmaceutical company built around ST266, a multi-targeted secretome of hundreds of biologically active proteins harvested from a novel population of amnion-derived cells. Rather than transplanting cells, Noveome delivers the healing signals those cells secrete - aiming to modulate inflammation, protect nerves, and accelerate tissue repair. Its lead program treats necrotizing enterocolitis, a devastating gut disease in premature infants, with additional pipeline work spanning ophthalmology, neurology, and dermatology.
Pleno Inc.
Pleno Inc. is a San Diego multi-omic instrument company rebuilding the economics of biological target detection. Its RAPTOR platform, powered by proprietary Hypercoding technology borrowed from telecommunications signal processing, can detect up to 10,000 targets in a single sample at PCR-like speed and cost. Founded by serial entrepreneur Pieter van Rooyen, the company is moving from R&D into commercial launch with backing from Deerfield Management and Foresite Capital.
Zafrens
Zafrens is a San Diego biotechnology company building an ultra-high-throughput single-cell platform that isolates, images, runs assays on, and sequences millions of individual cells per day. Its Z-Screen technology swaps the conventional 96-well plate for a credit-card-sized plastic chip holding 50,000 to 200,000 microwells, each with integrated imaging and multi-omic sequencing. By linking perturbation to genotype, phenotype and function at single-cell resolution, Zafrens compresses multiple stages of drug discovery into a single benchtop experiment - a 500x to 2,000x jump in the number of experiments a scientist can run at one timepoint.
Paradigm4
Paradigm4 builds scientific data management and analytics software for the life sciences. Its flagship REVEAL platform and SciDB array database let pharma, biotech, and research institutions integrate and analyze massive multimodal datasets - genomics, multi-omics, imaging, clinical records, wearables, and environmental data - to find biomarkers and validate drug targets. Co-founded in 2010 by entrepreneur Marilyn Matz and Turing Award-winning MIT professor Michael Stonebraker, the company is based in Waltham, Massachusetts.
Watershed Bio
Watershed Bio (legally Watershed Informatics) is a Cambridge, Massachusetts startup building a unified, cloud-based platform for biological data analysis. Its product, Omics Bench, lets biologists and bioinformaticians securely store, harmonize, and analyze multi-omic data - genomics, single-cell and spatial transcriptomics, epigenomics, proteomics, metabolomics, microbial sequencing and protein folding - using customizable and AI-assisted workflows backed by elastic supercomputing. The pitch: go from sample to therapeutic insight in a single day instead of weeks, closing the gap between high-code and no-code bioinformatics for drug-discovery teams.
Peter DiLaura
Peter DiLaura is the CEO and Board Director of Helicore Biopharma, a San Mateo biotech building long-acting antibody-peptide conjugates that go after obesity by neutralizing the GIP hormone in the bloodstream rather than blocking its receptor. With nearly three decades of company-building behind him - CEO roles at Initial Therapeutics and Second Genome, business and strategy chief at Sonoma Biotherapeutics, and time as an Entrepreneur-in-Residence at Third Rock Ventures - he is the operator brought in to turn a $65M Series A and a clinic-ready antibody into medicines that aim for quarterly dosing and better-quality weight loss.